80 related articles for article (PubMed ID: 21111679)
1. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T; Widmer N; Biollaz J; Decosterd LA
Lancet Oncol; 2011 Jan; 12(1):9-11. PubMed ID: 21111679
[No Abstract] [Full Text] [Related]
2. Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug.
Smith KD; Paterson S
Haematologica; 2005 Nov; 90 Suppl():ELT01. PubMed ID: 16266931
[No Abstract] [Full Text] [Related]
3. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
[TBL] [Abstract][Full Text] [Related]
4. Disease progression in some cancers may be due to low blood levels of targeted therapies.
Tuma RS
J Natl Cancer Inst; 2008 Jul; 100(13):912-3. PubMed ID: 18577740
[No Abstract] [Full Text] [Related]
5. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
[TBL] [Abstract][Full Text] [Related]
6. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
[TBL] [Abstract][Full Text] [Related]
7. Drug plasma monitoring in CML and GIST: A case-based discussion.
Egorin MJ; Mauro MJ; Trent JC
Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S3-11. PubMed ID: 20099379
[TBL] [Abstract][Full Text] [Related]
8. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Manley PW; Blasco F; Mestan J; Aichholz R
Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
[TBL] [Abstract][Full Text] [Related]
9. [Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].
Trabelsi S; Gaïes E; Sraïri S; Sahnoun R; Daghfous R; Lakhal M; El Aïdli S; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):203-6. PubMed ID: 23587588
[TBL] [Abstract][Full Text] [Related]
10. Review: Imatinib plasma trough levels in the management of CML: Ready for prime time?
Mauro MJ
Clin Adv Hematol Oncol; 2009 Nov; 7(11):766-7. PubMed ID: 20075836
[No Abstract] [Full Text] [Related]
11. Monitoring of imatinib targeted delivery in human leukocytes.
Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
[TBL] [Abstract][Full Text] [Related]
12. EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required.
Future Oncol; 2008 Dec; 4(6):758. PubMed ID: 19086840
[No Abstract] [Full Text] [Related]
13. Binding of imatinib by alpha(1)-acid glycoprotein.
Gambacorti-Passerini C; le Coutre P; Zucchetti M; D'Incalci M
Blood; 2002 Jul; 100(1):367-8; author reply 368-9. PubMed ID: 12096719
[No Abstract] [Full Text] [Related]
14. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Miura T; Kawamura T; Obara S; Tanaka J; Asaka M; Imamura M; Masauzi N
Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
[No Abstract] [Full Text] [Related]
16. Everolimus alters imatinib blood partition in favour of the erythrocyte.
Prenen H; Guetens G; De Boeck G; Highley M; van Oosterom AT; de Bruijn EA
J Pharm Pharmacol; 2006 Aug; 58(8):1063-6. PubMed ID: 16872552
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
18. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
Klabusay M
Klin Onkol; 2015; 28(2):83. PubMed ID: 25997207
[No Abstract] [Full Text] [Related]
19. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.
Jourdil JF; Tonini J; Stanke-Labesque F
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():1-9. PubMed ID: 23384531
[TBL] [Abstract][Full Text] [Related]
20. The Indian Supreme Court's judgment in the case of Glivec(®) - the uncertain future of pharmaceutical patents in India.
Thikkavarapu PR
Pharm Pat Anal; 2014 Mar; 3(2):117-9. PubMed ID: 24588585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
